Frontlight ResearchEarly access
TerminatedNo phase
The INSPIRE Study: Probable Benefit of the Neuro-Spinal Scaffold for Treatment of AIS A Thoracic Acute Spinal Cord Injury
Key facts
- Who runs it
- InVivo Therapeutics
- Where
- Camden, Charlotte, Greenville, Los Angeles, Phoenix, Pittsburgh, Portland, and Sacramento, United StatesSee the 8 sites
- Trial code
- Status
- Terminated
- People taking part
- 20 people enrolled
- Started
- 13 Oct 2014
- Ended
- Dec 2023
- Type of study
- Interventional
- Treatments tested
- Neuro-Spinal Scaffold
- Record updated
- 17 January 2024
- Why it stopped
- Primary Endpoint not met in follow-up study (InVivo-100-105)
Who can take part
- Age
- 16 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 32 criteriaShow less
Who can take part
- Subjects must meet all of the following to be considered eligible:
- AIS A classification of traumatic spinal cord injury at T2-T12 neurological level of injury confirmed by a qualified medical professional
- Recent injury (must receive Scaffold within 7 days from injury)
- Non-penetrating SCI (contusion injury) that is no less than approximately 4 mm in diameter by MRI
- Requires open spine surgery allowing access to the injured spinal cord (subjects requiring either posterior surgical approach or posterior plus anterior approach will be eligible)
- Informed consent obtained
- 16-70 years of age, inclusive
- Hemodynamically stable and deemed a suitable candidate for surgery
Who cannot take part
- Subjects with clinically significant pre-existing neurological comorbidities that are unrelated to the contusion being treated (e.g., multiple sclerosis, amyotrophic lateral sclerosis, significant prior peripheral nerve dysfunction, residual problems related to previous spine-related neurological pathologies) will be excluded only if it is felt that these preexisting morbidities will increase risk, affect safety monitoring, or confound study results
- Having a medical condition (e.g., cardiovascular disease, life threatening injuries), or receiving medical treatment, or having any other reason that, in the judgment of the Investigator, precludes successful participation and follow-up for at least six months or confounds collection or interpretation of study safety, feasibility, or efficacy data
- Subjects with clinically significant pre-existing respiratory disease not related to the contusion being treated (e.g., chronic obstructive pulmonary disorder)
- Subjects with documented immune deficiency disorders, including a known diagnosis of HIV infection/AIDS
- Recent (according to Diagnostic and Statistical Manual of Mental Disorders (DSM) IV or DSM V criteria) history of abuse of narcotics or other significant substance abuse
- Known hypersensitivity to poly(lactic-co-glycolic acid) (PLGA) or poly-L-lysine (PLL) (e.g., hypersensitivity to absorbable sutures containing PLGA)
- History of severe mental illness (according to DSM IV or V)
- Evidence of pre-trauma active local or systemic infection
- Subjects who meet any of the following will be excluded:
- Terminally ill subjects not likely to be able to participate in follow-up
- Incomplete spinal cord injury (AIS B, C, D, and E injuries)
- Subjects with more than one discrete spinal cord injury (contusion) will be excluded
- No discrete cavity (existing or created by irrigation/myelotomy) in the contused spinal cord in which a Scaffold can be placed
- Evidence of clear and significant Somatosensory Evoked Potentials (SSEP) transmission through the injury site before Scaffold implantation (based on the judgment of the Investigator)
- Spinal cord injury associated with significant traumatic brain injury or coma that, in the opinion of the Investigator, would preclude adequate assessment of spinal cord function, brain injury that could be associated on its own with sensory or motor deficits, or subjects with any other reason that results in an unreliable International Standards of Neurological Classification of Spinal Cord Injury (ISNCSCI) exam
- Subjects requiring Long-term ongoing mechanical ventilation
- Significant injury complications where, in the view of the Investigator, participation in the study could further complicate subject care, limit study follow-up, or confound interpretation of safety or efficacy data
- A female who is:; Pregnant, or planning to become pregnant within the next 12-months; or; Breastfeeding; or; A woman of child-bearing potential (defined as post menarche and biologically capable of becoming pregnant [i.e., not surgically sterile]) who is engaged in active heterosexual relations and is not willing to use a barrier or hormonal form of birth control for 12-months following Scaffold implantation (e.g., oral, injected, or implanted contraceptives)
- A male who is engaged in active heterosexual relations and is not willing to use birth control for 3-months following Scaffold implantation including sperm donation or banking
- Current or impending incarceration
- Complete spinal cord transection
- Subjects with spinal cord injuries directly due to gunshot, knife, or other penetrating wounds
- Participation in another interventional clinical trial for six months after Scaffold implantation
- Body mass index (BMI) over 39
Where in United States
- Cooper Neurological InstituteCamden, United States
- Carolina NeuroSurgery and Spine Associates/Carolinas RehabilitationCharlotte, United States
- Vidant Medical CenterGreenville, United States
- USC Keck School of MedicineLos Angeles, United States
- Barrow Neurological Institute - St. Joseph's Hospital and Medical CenterPhoenix, United States
- Allegheny General HospitalPittsburgh, United States
- Oregon Health Science UniversityPortland, United States
- University of California, Davis Medical CenterSacramento, United States
About the trial
What the trial wants to find out
This is an HDE probable benefit, open-label, non- randomized, single-arm, multicenter study to evaluate the safety and probable benefit of the poly(lactic-co-glycolic acid)-b-poly(L-lysine) Scaffold ("Scaffold") in subjects with thoracic AIS A traumatic spinal cord injury at neurological level of injury of T2-T12.
The group in the trial
- Neuro-Spinal ScaffoldTreatment being tested
Implantation of a Neuro-Spinal Scaffold into the epicenter of the post-irrigation contusion cavity during open spine surgery
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold(TM) for Safety and Neurologic Recovery in Subjects With Complete Thoracic AIS A Spinal Cord Injury
- Publications
- Acute Implantation of a Bioresorbable Polymer Scaffold in Patients With Complete Thoracic Spinal Cord Injury: A Randomized Controlled Trial (INSPIRE 2.0).Neurosurgery, 2025
- Acute Implantation of a Bioresorbable Polymer Scaffold in Patients With Complete Thoracic Spinal Cord Injury: 24-Month Follow-up From the INSPIRE Study.Neurosurgery, 2022
- A study of probable benefit of a bioresorbable polymer scaffold for safety and neurological recovery in patients with complete thoracic spinal cord injury: 6-month results from the INSPIRE study.Journal of neurosurgery. Spine, 2021
- Record updated
- 17 January 2024